Fresenius Medical Care AG & Co. KGaA ADR (FMS)
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income.
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg Robert Davies - Morgan Stanley Hugo Solvet - BNP Paribas Oliver Metzger - ODDO BHF Bank Sezgi Oezener - HSBC Giang Nguyen - Citigroup David Adlington - JPMorgan Marianne Bulot - Bank of America Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator Ladies and gentlemen, welcome to the report of the Third Quarter 2024 of Fresenius Medical Care Conference Call. I'm Sandra, the Chorus Call operator.
Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Fresenius (FMS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Fresenius Medical Care: Let's Look At The Upside
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT.
Here's Why Fresenius (FMS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
